Experimental cell therapy targets multiple cancers in early trial

NCT ID NCT05483491

Recruiting now Disease control Sponsor: Christian Hinrichs Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new type of immune cell therapy for people with advanced cancers that have a specific protein called KK-LC-1. The cancers being studied include stomach, breast, cervical, and lung cancer. Participants will receive chemotherapy followed by a single infusion of their own modified immune cells, plus a drug to help those cells work. The main goal is to find a safe dose and see if the treatment can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KK-LC-1 TCR-T cells (a type of immune cell therapy) given with chemotherapy and aldesleukin (a drug to boost immune cells)
What this could lead to: If it works, this could lead to a new treatment option for several hard-to-treat cancers that have a specific protein marker.
What could go wrong: This is a very early phase 1 trial with only 30 people, so it is mainly checking safety and dosing. The treatment may not shrink tumors, and side effects from the chemotherapy and cell infusion can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cervical cancer cervical carcinoma gastric cancer gastric carcinoma gastric neoplasm lung cancer lung neoplasm non-small cell lung carcinoma triple-negative breast carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER CERVICAL CANCER GASTRIC CANCER LUNG CANCER

Contacts and locations

Locations

RWJBarnabas Health - Robert Wood Johnson University Hospital
RECRUITING

New Brunswick, New Jersey, 08901, United States
Rutgers Cancer Institute
RECRUITING

New Brunswick, New Jersey, 08901, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.